This two-day conference will serve as a platform to discuss compliance and transparency areas of key concern. Goal is to unravel compliance challenges, define and learn fair market value and develop a consistent, simple and transparent method and strategy for your company.
Topic insight: Implementation of EU-GMP Annex 16 at H. Lundbeck
Starting the project with a GAP analysis revealed that a number of Lundbeck’s procedures would have to be updated in order to be in compliance with the requirements of the revised annex 16. The main focus areas would be certificates, quality agreements and education of our personnel.
Certificates are a challenge, since our electronic solution requires a generic approach, and affiliates both inside and outside the EU have their own requirements. Quality agreements must describe in more detail the division of responsibility between QP’s inside the EU; if outside the EU, additional requirements apply. Furthermore, a system had to be implemented insuring that all relevant knowledge is available to the pharmacist (QP delegate) when releasing product.
At Lundbeck, these requirements are facilitated by our creation of “Quality Responsible Persons”, which in our terminology means a person within Quality Assurance who is appointed as the main expert of a business area. E.g., tablet production at HQ, or CMO production worldwide. The “Quality Responsible Person” reports directly to the QP on all compliance issues within his area. At the same time, the “Quality Responsible Person” is in charge of the PQR process within the business area and is responsible for keeping the other pharmacists (QP delegates) updated on all relevant matters regarding product and procedure.
In each business area, a “Risk Register” is established and maintained through cooperation between the “Quality Responsible Person” and a representative from that business area.
The purpose of the “Risk Register” is to mitigate all risk by stating the problem and its impact, thereby enabling prioritization based on facts and facilitating the implementation process.
Each business area, e.g., sterile production at HQ, packaging at HQ and so forth, is evaluated monthly in a management report. A “Quality Index” generated by Quality Assurance addresses relevant parameters for the specific business area. It is typically influenced by parameters such as deviations or rejected batches, but it is also linked to the “Risk Register”, and management is thereby involved directly in the prioritization and risk mitigation.
The implementation of EU-GMP Annex 16 at Lundbeck was facilitated by these processes.
Interested in this topic?
Project & Portfolio Management for Pharma and Biotech – EAST
For the upcoming Project and Portfolio Management for Pharma and Biotech Conference, Fleming presents a high-level meeting building on more than a decade of experience in running global Pharma PPM events worldwide.
Patient Adherence and Engagement
Discuss the issues of non-adherence with other stakeholders and find a solution together with the patients themselves.
Ready for the new GCP ICH E6 (R2) addendum?
On the 23rd of July 2015, the EMA's Committee for Human Medicinal Products released the Guideline for Good Clinical Practice E6(R2) for consultation. On the 14th of June 2017, it will come into effect and influence everyone involved in the clinical research process. What does it mean to pharma and biotech companies, sponsors, CROs, research institutes and third-party organizations?
With improved patient engagement to increased patient adherence
Chronic illnesses are commonly treated with the long-term use of medications. This treatment could be successful, however, its benefits are overshadowed by the fact that 50% of patients don't take their medications as prescribed. Reveal all the alarming numbers of non-adherence and learn how to decrease it with improved patient engagement.
The expanding role of pharmacovigilance and risk management
A profound and accelerated transformation of the Pharmacovigilance world is happening, due to several key drivers. The absolute necessity to ensure that patients can benefit from an early access to new drugs, while ensuring an optimal identification and management of risks is vital.